GLAXOSMITHKLINE PHARMACEUTICALS
|
The Current P/E Ratio of GLAXOSMITHKLINE PHARMACEUTICALS is 56.84.
Share Price | ₹2,265.1 | Dec 24,2024 |
Market Cap | ₹38,370.8 Cr | |
Earnings-TTM | ₹675.0 Cr | TTM-Consolidated Results |
Price/Earnings | 56.84x | Calculated as Market Cap/Earnings |
---|---|---|
Explore Stock Analytics |
Definition & Calculation of PE (Price/Earnings) ratio of GLAXOSMITHKLINE PHARMACEUTICALS
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹38,370.8 Cr] as on Dec 24,2024
(/) Earnings [ ₹675.0 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 56.84x ]
Thus, for GLAXOSMITHKLINE PHARMACEUTICALS , the investors are currently willing to pay 56.84 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of GLAXOSMITHKLINE PHARMACEUTICALS !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of GLAXOSMITHKLINE PHARMACEUTICALS over the last five years.
Historical PE (Price/Earnings) ratio chart of GLAXOSMITHKLINE PHARMACEUTICALS
PE Ratio Performance Analysis for GLAXOSMITHKLINE PHARMACEUTICALS
- GLAXOSMITHKLINE PHARMACEUTICALS 's p/e ratio for fiscal years ending Mar2024 to Mar2020 averaged 80.72x.
- GLAXOSMITHKLINE PHARMACEUTICALS 's operated at median p/e ratio of 55.8x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, GLAXOSMITHKLINE PHARMACEUTICALS 's p/e ratio peaked in Mar2020 at 226.34x.
- GLAXOSMITHKLINE PHARMACEUTICALS 's p/e ratio hit its five-year low in Mar2022 of 16.62x.
How does GLAXOSMITHKLINE PHARMACEUTICALS 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
---|---|---|---|
GLAXOSMITHKLINE PHARMACEUTICALS | 675.03 | 56.84 | 38,370.8 |
SUN PHARMACEUTICAL INDUSTRIES LTD | 11,136.50 | 39.16 | 436,103.0 |
CIPLA LTD | 4,485.22 | 26.58 | 119,196.0 |
DR REDDYS LABORATORIES LTD | 5,406.80 | 20.85 | 112,752.0 |
ZYDUS LIFESCIENCES LTD | 4,298.90 | 22.57 | 97,041.2 |
DIVIS LABORATORIES LTD | 1,836.00 | 83.63 | 153,540.0 |
MANKIND PHARMA LTD | 2,124.86 | 56.51 | 120,073.0 |
TORRENT PHARMACEUTICALS LTD | 1,802.00 | 63.88 | 115,112.0 |
LUPIN LTD | 2,651.94 | 37.30 | 98,925.3 |
AUROBINDO PHARMA LTD | 3,598.83 | 20.37 | 73,314.6 |
ABBOTT INDIA LTD | 1,284.66 | 47.08 | 60,480.4 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs GLAXOSMITHKLINE PHARMACEUTICALS 's P/E Ratio
Top 10 Industry Peers | PE Ratio |
---|---|
Min industry PE | 20.37x |
Max industry PE | 83.63x |
Median industry PE | 39.16x |
Average industry PE | 43.16x |
You may also like the below Video Courses